Submitted by Anonymous (not verified) on 9 November 2023 - 12:54
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Lymphoma, Follicular, Date of authorisation: 03/06/2022, Revision: 2, Status: Authorised
Source: